Publication | Open Access

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

Gastrointestinal OncologyMedicineRandomised Phase 3Adjuvant CapecitabineGastroenterologySurgeryGastric CancerCancer TreatmentOncologyRadiation Oncology